Business Wire

Modernizing the Global Postal System: Zonos Selected by the Universal Postal Union (UPU) to Power Enhanced Compliance, Processing Speed, and Transparency for Posts Worldwide

Share

In a groundbreaking move to address the dual challenges of evolving compliance regulations and increasing consumer expectations for swift, efficient deliveries, Zonos, the leader in cross-border technology solutions, has been selected by the Universal Postal Union (UPU) for a strategic initiative. The UPU is a United Nations specialized agency that facilitates international postal cooperation through its universal network of modern postal services. By leveraging Zonos' cutting-edge API technology to enhance the accuracy and processing speed of data transmitted through the UPU's Customs Declaration System (CDS), this effort is poised to transform the global postal ecosystem. This initiative aims to empower postal operators with technology to mitigate delays caused by inadequate or incomplete data, thereby improving operational efficiency, ensuring compliance, and significantly enhancing the delivery experience for consumers worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904490189/en/

The international DDP shipping model allows parcels to ship with duties, taxes, and fees prepaid, making it easy for packages to move through customs. (Graphic: Business Wire)

Bridging the Technological Divide for Postal Operators Worldwide

This partnership specifically targets the technological challenges faced by postal operators around the globe. Many of these entities struggle to compete in an increasingly digital and data-driven landscape due to their limited ability to accurately and rapidly transmit electronic advanced data (EAD). This deficiency places them at a competitive disadvantage and contributes to significant delays in the international customs clearance process.

Zonos' innovative API technology offers a scalable and adaptable technology solution to these challenges, facilitating real-time, accurate data collection that meets the rigorous requirements of modern customs and security regulations that require detailed shipment information including good descriptions, harmonized codes, and accurate values for general or regional (such as ICS2) EAD regulations. The improved data quality addresses regulatory and safety concerns about the contents of packages for global customs operations.

Transitioning to a Delivered Duty Paid (DDP) Model

A significant goal of this collaboration is to transition towards a DDP model in response to market demand for more transparent and efficient customs processes. This initiative supports the UPU's Article 18-004 (Items for delivery free of charges and fees) by developing a robust DDP solution, facilitating smoother and faster cross-border mail and parcel deliveries. By enabling posts to calculate and collect duties and taxes at the point of sale, this model eliminates surprise costs for consumers and enhances the overall international mailing and delivery experience.

Enhancing Consumer Experience through Efficiency and Reliability

The UPU-Zonos initiative emphasizes improving the delivery experience for consumers worldwide. By streamlining the data collection process, the partnership aims to expedite customs clearance and reduce the time packages spend in transit to meet the consumer demand for speed. It also aims to enhance the reliability and predictability of international deliveries, fostering greater trust in the global postal system.

A Unified Vision for the Future of International Postal Services

The shared commitment of the UPU and Zonos to leveraging technology for the betterment of the global postal ecosystem is at the heart of this initiative. Clint Reid, CEO of Zonos, echoed this sentiment, highlighting the transformative potential of the collaboration: "Together, we are not just addressing immediate challenges; we are paving the way for a future where international postal services are more secure, efficient, and transparent for all."

About Zonos

Zonos is a leader in technology innovation for international commerce, simplifying cross-border trade with its comprehensive suite of solutions. Focused on compliance, classification, and transparent cost calculation, Zonos empowers businesses and postal operators to expand their global reach effortlessly, making international trade more accessible and transparent.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240904490189/en/

Contacts

Jennifer Meads, Head of Marketing at Zonos
media@zonos.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye